Agretti P, Chiovato L, De Marco G, Marcocci C, Mazzi B, Sellari-Franceschini S, Vitti P, Pinchera A, Tonacchera M 2002 Real-time PCR provides evidence for thyrotropin receptor mRNA expression in orbital as well as in extraorbital tissues
Without controlled human studies, any dosing discussion is speculative and should be considered unsafe outside research settings
None of these questions can be considered resolved at the Phase 2 stage, and the glucagon axiss effects on resting heart rate in particular are exactly the kind of signal that only a large, long cardiovascular-outcomes trial is powered to characterize
Serious adverse events have not been widely reported in the community, but the lack of long-term safety data means unknown risks may exist
Your first step is to Request a Consultation , a representative will guide your through the next couple of steps
The FDA has identified concerns involving: Potential immunogenicity Peptide-related impurities Limited safety information for proposed routes of administration Insufficient information to determine whether compounded BPC-157 may cause harm in humans This does not prove that every patient who receives BPC-157 will experience a serious adverse event
